Heart Failure

528

Pipeline Programs↗

236

Active Trials↗

139

Companies Involved↗

Heart Failure is a highly competitive landscape with 528 programs across 139 companies. The most active players are Acorda Therapeutics, Secretome Therapeutics, Olatec Therapeutics LLC. 146 therapies are approved with 81 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

97/100

Pipeline Velocity

84/100

Mech. Concentration

6/100

Completion Rate

78/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Acorda Therapeutics

2 programs

Secretome Therapeutics

1 program

Olatec Therapeutics LLC

1 program

Vasa Therapeutics

1 program

Moderna

1 program

Jazz Pharmaceuticals

1 program

Pipeline

Programs by Phase

Preclinical89

Alteplase

Roche

Warfarin

Abbott

Paricalcitol

AbbVie

Terbutaline

Sanofi

Metoprolol Succinate

AstraZeneca

Phase 162

Milrinone

Sanofi

Midazolam

Conrado Roberto Hoffmann Filho

Trimetazidine

IRCCS San Raffaele

Regadenoson

Astellas

Adenosine

Astellas

Phase 2150

Testosterone

Auxilium

Metformin Hydrochloride

Boehringer Ingelheim

Anakinra

Swedish Orphan Biovitrum

Riboflavin

Cornea and Laser Eye Institute

Isosorbide Mononitrate

Omnivium

Phase 381

Semaglutide

Novo Nordisk

Levosimendan

Orion Corporation, Orion Pharma

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Candesartan

AstraZeneca

Olmesartan Medoxomil

Cosette Pharmaceuticals, Inc.

Approved146

Vericiguat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Inclisiran

Novartis

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Macitentan

Johnson & Johnson

Tolvaptan

Otsuka

Analysis

Modality Breakdown

94%

Small molecule

585 of 624 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 624 classified programs, each share of the total. Modality classified for 98% of 688 pipeline programs.

Analysis

Trial Status

1,063

clinical trials

Completed528 · 50%

Unknown status152 · 14%

Recruiting131 · 12%

Terminated91 · 9%

Not yet recruiting57 · 5%

Withdrawn50 · 5%

Other54 · 5%

Clinical Trials

Trial Activity

1063 trials

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Recruiting·UUniversity Medical Centre Ljubljana·Phase 1/2·NCT06541509·10 enrolled

Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

Recruiting·II.M. Sechenov First Moscow State Medical University·Phase 1/2·NCT05637398·40 enrolled

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

Recruiting·—·Phase 4·NCT04707261·1,990 enrolled

Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure

Recruiting·UUniversity Hospital, Montpellier·N/A·NCT04554277·710 enrolled

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

Recruiting·NNational Taiwan University Hospital·Phase 4·NCT06249945·150 enrolled

Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06518694·1,300 enrolled

Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure

Recruiting·UUniversity Medical Center Goettingen·Phase 1/2·NCT04396899·53 enrolled

Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload

Recruiting·—·Phase 4·NCT06414759·110 enrolled

Timely Recovery After Subclinical Heart Failure

Recruiting·—·Phase 4·NCT06341101·130 enrolled

Digoxin After Acute Heart Failure

Recruiting·—·Phase 4·NCT07321509·120 enrolled

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06200207·680 enrolled

Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes

Recruiting·UUniversitas Diponegoro·Phase 4·NCT06475105·66 enrolled

Study of JK07 in Patients With Chronic Heart Failure

Recruiting·SSalubris Biotherapeutics Inc·Phase 2·NCT06369298·282 enrolled

Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting·SSecretome Therapeutics·Phase 1·NCT06560762·12 enrolled

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Recruiting·YYale University·Phase 1·NCT05753059·50 enrolled

Page 1 of 71

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)